PVCT insider trading
HealthcarePROVECTUS BIOPHARMACEUTICALS, INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About PROVECTUS BIOPHARMACEUTICALS, INC.
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines for various diseases in the United States. The company's lead molecule is rose bengal sodium, a member of a class of molecules called halogenated xanthenes. Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers and blood cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. The company is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, it develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It also has collaboration agreement with Bascom Palmer Eye Institute, and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.
Company website: www.provectusbio.com
PVCT insider activity at a glance
FilingIQ has scored 74 insider transactions for PVCT since Jan 24, 2015. The most recent filing in our index is dated May 7, 2026.
Across the full history, 3 open-market purchases
and 0 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on PVCT insider trades is 58.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for PVCT?
- FilingIQ tracks 74 Form 4 insider transactions for PVCT (PROVECTUS BIOPHARMACEUTICALS, INC.), covering filings from Jan 24, 2015 onwards. 15 of those were filed in the last 90 days.
- Are PVCT insiders net buyers or net sellers?
- Across the full Form 4 history for PVCT, 3 transactions (4%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does PVCT insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is PVCT in?
- PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $19.92M.
Methodology & sources
Every PVCT insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.